Phase 3 Randomized Study Comparing Nivolumab and Ipilimumab Combination vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse. - CheckMate 914: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 914

Overview

No summary available.

Registry

who.int

Start Date

July 31, 2017

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Sponsor

•a) Kidney tumor has been completely resected, and the nephrectomy must occur no less than 4 weeks and less or equal to 12 weeks prior to randomization. Partial nephrectomy is allowed provided all inclusion criteria are met and negative surgical margins are obtained.
•b) Post\-nephrectomy tumor shows RCC with a predominately clear cell histology, including participants with sarcomatoid features.
•c) Pathological TNM staging per AJCC staging version 2010:
•i) pT2a, G3 or G4, N0M0
•ii) pT2b, G any, N0M0
•iii) pT3, G any, N0M0
•iv) pT4, G any, N0M0
•v) pT any, G any, N1M0
•d) Participants must have no clinical or radiological evidence of macroscopic residual disease or distant metastases (M0\) after nephrectomy
•i) Baseline tumor assessment, performed 4 to approximately 12 weeks after nephrectomy, shows no metastasis or residual tumor lesions per local review and as confirmed by Blinded Independent Central Review (BICR). Results of BICR of the baseline tumor assessment confirming absence of metastasis or residual tumor lesions must be received before randomization.

•a) Any severe or serious, acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration including ongoing or active infection requiring parental antibiotics
•b) Participants with a condition requiring systemic treatment with either corticosteroids (\> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days prior to the first dose of study drug. Topical, ocular, intra\-articular, intranasal, inhaled steroids, and adrenal replacement steroid doses \> 10 mg daily prednisone or the
•equivalent are permitted in the absence of active immune disease.
•c) Uncontrolled adrenal insufficiency
•d) Participants with an active known or suspected autoimmune disease. Participants with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.